Mainz Biomed N.V. is a biotechnology company focused on developing innovative molecular diagnostics and therapeutics for the early detection and treatment of various cancers
The company specializes in harnessing advanced biomarkers and genetic testing to empower healthcare providers and patients with accurate insights into disease risks and treatment options. By advancing personalized medicine and exploring novel diagnostic solutions, Mainz Biomed aims to enhance patient outcomes and improve the overall approach to cancer management.
With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSEPFE) reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December.
On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could revolutionize cancer treatment, joining in the global trend as pharmaceutical companies across the world turn to oncology for economic growth and opportunity to make history.
On Saturday, Pfizer Inc (NYSEPFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024 Congress.
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSEPFE) responded by slashing costs and shifting their focus to revolutionizing cancer treatment.
This week, Pfizer Inc (NYSEPFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V.
